AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
PASW

Ping An Biomedical Co. Ltd. Ordinary Shares (PASW) fair value

Consumer Cyclical · Textile Manufacturing · NASDAQ · United States
$4.76-11.19%
Market cap $17MUpdated Oct 24, 2026
Our verdict
Trades 660% above our fair value
Price
$4.76
Model fair valueConfidence: low
about $0.63
Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Treated as a pre-revenue company. None of the usual models had enough data, so this uses Net asset value, Discounted cash flow, and Dividend discount instead.
ACCE opinionPing An Biomedical Co. Ltd. Ordinary Shares (PASW)
Fair value
Not available
ACCE price target
$3.90
Rating
Not rated
Horizon
12 months
ACCE price target published on 24 Oct 2026, 03:20 CEST; previously $0.10 since 23 Oct 2026, 01:53 CEST.
Price used: $4.76 at the close on 23 Oct 2026, 22:00 CEST.
Models: Net asset value, Discounted cash flow, and Dividend discount.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
39
out of 100
P/E
0.0x
forward 0.0x
1-year return
+570.4%
Dividend yield
0.00%

Ping An Biomedical Co. Ltd. Ordinary Shares in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Ping An Biomedical is a $17M-market-cap Chinese shell-like issuer whose data points to textile manufacturing rather than the biomedical name, so the first step is confirming what the business actually sells. Revenue fell 47.4% and return on equity is -11.3%, while the 9.3% gross margin and 5.6% operating margin show it is still profitable at the operating line, leaving little evidence of a structural tailwind to lean on. With no index membership, no forward earnings estimate and a composite score of 21/100, the name screens as a distressed micro-cap rather than a compounder. Unless the filings show a clear reversal in the top line, we would not spend diligence time here.

AI-assisted·How I use AIWritten Oct 18, 2026

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where PASW's valuation models land
Price
$4.76
Model fair valueConfidence: low
about $0.63
Model
Fair value
Upside
Net asset value
Discounted cash flow
Dividend discount
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
-1.0%
1 month
-6.7%
3 months
-4.0%
6 months
+2875.0%
YTD
+852.0%
1 year
+570.4%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
24 Oct 2026, 03:20 CESTACCE price target$3.90$0.10$4.76
23 Oct 2026, 01:53 CESTACCE price target$0.10$0.05$0.13
22 Oct 2026, 01:52 CESTACCE price target$0.05$0.09$0.09
15 Oct 2026, 00:00 CESTACCE price target$0.09first publication$0.13

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full PASW page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth7Value15Quality36Momentum97Total39
Valuation
Trailing P/E
0.0x
Forward P/E
0.0x
PEG
no data
P/B
1.37x
EV / Revenue
4.3x
Book value/sh
¥0.09
Enterprise value
$16M
Profitability
ROE
-11.3%
FCF yield
-5.75%
ROIC
-18.9%
Health and risk
Debt / equity
0.23
Dividend yield
0.00%
Beta
no data

Price

+534.7% · 1Y

Ask anything about PASW

Answered from Ping An Biomedical Co. Ltd. Ordinary Shares fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 100% of peers
low 0.0x0.0xhigh 17.1x
ROEbetter than 17% of peers
low -14%-11%high 6%
Div yieldbetter than 50% of peers
low 0.0%0.0%high 6.7%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
PASW Ping An Biomedical Co. Ltd. Ordinary Shares$4.76----11.3%3639
1968.HK Hingtex Holdings LimitedHK$0.18----14.1%3532
DIE.DE Dierig Holding AG€8.25€1123% below12.0x5.3%6346
CULP Culp Inc. Common Stock$3.54----7.1%2739
DURC-B.ST Duroc AB (publ)kr 17.55kr 1163% above--9.4%3942
UFI Unifi Inc. New Common Stock$5.48----10.2%2748
DUNI.ST Duni AB (publ)kr 72.50kr 787% below17.1x5.6%4335

Sector report card

Where PASW ranks against its sector peers on each metric.

Computing percentiles…
  • GlobeNewswire•Jul 22, 2026
    Ping An Biomedical and Yuan Sheng Mei Yan Sign Strategic Cooperation Agreement, Targeting RMB 500 Million in Sales Over Three Years
  • Business Wire•Jul 1, 2026
    Net Asset Value(s)
  • PR Newswire•Jun 21, 2026
    Monster Energy's Manel Kape Stops Kyoji Horiguchi at UFC Fight Night 279 in Las Vegas
11 filings of 18
September 2026
Sep 11
6-KForeign current reportPeriod 2026-03-31
View on SEC →
August 2026
Aug 7
6-KForeign current reportPeriod 2026-08-07
View on SEC →
July 2026
Jul 22
6-KForeign current reportPeriod 2026-07-22
View on SEC →
8 more filings + AI summaries on Investor+.INVESTOR